Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963101 | 0.88 | ALOX5 (0.50) | BCL2L1ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6956984 | 0.86 | OPRM1 (0.43) | BCL2L1ALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001011 | 0.86 | HPGD (0.42) | HPGDALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001008 | 0.86 | HPGD (0.42) | HPGDALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6001013 | 0.86 | HPGD (0.42) | HPGDALOX5CYP1A2PTGESLMNA | |
| SCHEMBL24620828 | 0.82 | SMN1; SMN2 (0.54) | HPGDALOX5CYP1A2PTGESLMNA | |
| SCHEMBL6957330 | 0.82 | ALOX5 (0.45) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL6967733 | 0.82 | GAA (0.57) | HPGDALOX5CYP1A2PTGESLMNA | |
| SCHEMBL23053140 | 0.82 | ALOX5 (0.42) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL6963880 | 0.82 | ALOX5 (0.42) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038581-A1 | A ONE STEP SYNTHESIS OF 2-SUBSTITUTED BENZO[B]THIOPHENES | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IIT Madras) (IN) | 2021-03-04 | — | — | WO | disclosed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-7705034-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2074090-A1 | VINYLOGOUS ACIDS DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20080096953-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008043698-A1 | VINYLOGOUS ACIDS DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-17 | — | — | WO | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1551822-B1 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | disclosed |
| EP-1551822-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004009578-A2 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1077970-A1 | 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6110962-A | FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096953-A1 | Vinylogous acid derivatives | CMA1, TPSG1, GAA | HPGD 192/4885BCL2L1 3962/4885ALOX5 249/4885 |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | NR5A1, NR3C2, OXER1 | HPGD 195/4885BCL2L1 4152/4885ALOX5 237/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | HPGD 568/4885BCL2L1 2498/4885ALOX5 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.